US 20190234952A1
· Hu
· 2019
[cited by applicant]
WO 2015084800A1
· 2015
[cited by applicant]
WO 2017053516A1
· 2017
[cited by applicant]
Q. Chang et al. Effects of dasatinib on EphA2 receptor tyrosine Kinase act downstream signalling in pancreatic cancer, British J of Cancer, 99, 1074-1082. (Year: 2006).
[cited by examiner]
Greg J Nusz et al. Label-Gree Plasmonic Detection of Biuomolecular Binding by a single Gold Nanorod, Anal Chem. 80, 984-989. ( Year: 2008).
[cited by examiner]
Yusuke Yoshioka et al., Comparative marker analysis of extracellular vesicles in different human cancer types, Journal of Extracellular Vesicles, 2:1, 20424 (Year: 2013).
[cited by examiner]
Greg J Nusz et al., Label-Free Plasmonic Detection of Biomolecular Binding by a single Gold Nanorod, Anal Chem. 80,984-989. (Year: 2008).
[cited by examiner]
Kai Liang et al., Nature Biomedical Engineering, 1, Article No. 0021. (Year: 2017).
[cited by examiner]
Raposo G, et al. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200:373-383. [PubMed: 23420871].
[cited by applicant]
Rodriguez-Lorenzo L, et al. Plasmonic nanosensors with inverse sensitivity by means of enzyme-guided crystal growth. Nat Mater. 2012; 11:604-607. [PubMed: 22635043].
[cited by applicant]
Shao H, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015; 6:6999. [PubMed: 25959588].
[cited by applicant]
Shao H, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18:1835-1840. [PubMed: 23142818].
[cited by applicant]
Shi L, et al. Plasmon resonance scattering spectroscopy at the single-nanoparticle level: real-time monitoring of a click reaction. Angew Chem Int Ed Engl. 2013; 52:6011-6014. [PubMed: 23616358].
[cited by applicant]
Tanaka Y, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013; 119:1159-1167. [PubMed: 23224754].
[cited by applicant]
Thery C, et al. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2:569-579. DOI: 10.1038/hri855 [PubMed: 12154376].
[cited by applicant]
Théry C, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006:3.22.21-23.22.29. [PubMed: 18228482].
[cited by applicant]
Vaidyanathan R, et al. Detecting exosomes specifically: a multiplexed device based on alternating current electrohydrodynamic induced nanoshearing. Anal Chem. 2014; 86:11125-11132. [PubMed: 25324037].
[cited by applicant]
Van Der Pol E, et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012; 64:676-705. [PubMed: 22722893].
[cited by applicant]
Yokoi K, et al. Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Lett. 2013; 334:319-327. [PubMed: 23000514].
[cited by applicant]
Yoshioka Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014; 5:3591. [PubMed: 24710016].
[cited by applicant]
Yoshioka, Y, et al. “Comparative marker analysis of extracellular vesicles in different human cancer types.” Journal of extracellular vesicles 2.1 (2013): 20424.
[cited by applicant]
Chang, Q., et al., “Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer, ” British Journal of Cancer, vol. 99, published online Sep. 16, 2018, pp. 1074-1082.
[cited by applicant]
International Search Report and Written Opinion issued for International Application No. PCT/US2017/068768, mail date Mar. 5, 2018, 11 pages.
[cited by applicant]
Anderson HC, et al. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab Invest. 2010; 90:1549-1557. [PubMed: 20805791].
[cited by applicant]
Anker JN, et al. Biosensing with plasmonic nanosensors. Nat Mater. 2008; 7:442-453. [PubMed: 18497851].
[cited by applicant]
Ansuini H, et al. Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer. J Oncol. 2009; 2009:951917. [PubMed: 20130824].
[cited by applicant]
Archin NM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012:487.
[cited by applicant]
Ballehaninna UK, et al. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol. 2013; 34:3279-3292. [PubMed: 23949878].
[cited by applicant]
Ballehaninna UK, et al. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012; 3:105-119. [PubMed: 2281187…
[cited by applicant]
Boukouris S, et al. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015; 9:358-367. [PubMed: 25684126].
[cited by applicant]
Brantley DM, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002; 21:7011-7026. [PubMed: 12370823].
[cited by applicant]
Brinton LT, et al. Formation and role of exosomes in cancer. Cell Mol Life Sci. 2015; 72:659-671. [PubMed: 25336151].
[cited by applicant]
Choi Y, et al. Selective and sensitive detection of metal ions by plasmonic resonance energy transfer-based hanospectroscopy. Nat Nanotechnol. 2009; 4:742-746. [PubMed: 19893511].
[cited by applicant]
De Candia P, et al. Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation. PLoS One. 2013; 8:e75348. [PubMed: 24205408].
[cited by applicant]
Del Villano BC, et al. Radioimmunometric assay for monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983; 29:549-552. [PubMed: 6825270].
[cited by applicant]
Dobrzanski P, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Caner Research. 2004; 64:910-919.
[cited by applicant]
Duxbury MS, et al. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004; 23:1448-1456. [PubMed: 14973554].
[cited by applicant]
Duxbury MS, et al. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun. 2004; 320:1096-1102. [PubMed: 15249202].
[cited by applicant]
Evans DB, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127:1335-1339. [PubMed: 1359851].
[cited by applicant]
Freelove R, et al. Pancreatic Cancer: Diagnosis and Management. Am Fam Physician. 2006; 73:485-492. [PubMed: 16477897].
[cited by applicant]
Ghosh SK, et al. Interparticle coupling effect on the surface plasmon resonance of gold nanoparticles: from theory to applications. Chem Rev. 2007; 107:4797-4862. [PubMed: 17999554].
[cited by applicant]
Good DM, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res. 2007; 6:4549-4555. [PubMed: 17970587].
[cited by applicant]
Gyorgy B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011; 68:2667-2688. [PubMed: 21560073].
[cited by applicant]
He M, et al. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip. 2014; 14:3773-3780. [PubMed: 25099143].
[cited by applicant]
Hidalgo M. Pancreatic cancer. N Engl J Med. 2010:362.
[cited by applicant]
Hori SS, et al. Mathematical model identifies blood biomarker-based early cancer detection strategies and imitations. Sci Transl Med. 2011; 3:1-9.
[cited by applicant]
Im H, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014; 32:490-495. [PubMed: 24752081].
[cited by applicant]
Jazieh KA, et al. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. Semin Radiat Oncol. 2014; 24:67-76. [PubMed: 24635863].
[cited by applicant]
Jensen MM, et al. Tumor vol. in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008; 8:16. [PubMed: 18925932…
[cited by applicant]
Joshi GK, et al. Label-free nanoplasmonic-based short noncoding RNA sensing at attomolar concentrations allows for quantitative and highly specific assay of microRNA-10b in biological fluids and circulating exosomes. AC…
[cited by applicant]
Kalra H, et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics. 2013; 13:3354-3364. [PubMed: 24115447].
[cited by applicant]
Kanwar SS, et al. Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip. 2014; 14:1891-1900. [PubMed: 24722878].
[cited by applicant]
Khan S, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One. 2012; 7:e46737. [PubMed: 23091600].
[cited by applicant]
Kinch, MS et al. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis. 2003; 20:59-68. [PubMed: 12650608].
[cited by applicant]
Kowal J, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci. 2016; 113:E968-977. [PubMed: 26858453].
[cited by applicant]
Lane RE, et al. Analysis of exosome purification methods using a model liposome system and tunable-resistive pulse sensing. Sci Rep. 2015; 5:7639. [PubMed: 25559219].
[cited by applicant]
Lee K, et al. Quantitative imaging of single mRNA splice variants in living cells. Nat Nanotechnol. 2014; 9:474-480. [PubMed: 24747838].
[cited by applicant]
Lescuyer P, et al. How shall we use the proteomics toolbox for biomarker discovery? J Proteome Res. 2007; 6:3371-3376. [PubMed: 17655344].
[cited by applicant]
Li D, et al. Pancreatic cancer. The Lancet. 2004; 363:1049-1057.
[cited by applicant]
Link S, et al. Spectral properties and relaxation dynamics of surface plasmon electronic oscillations in gold and silver hanodots and nanorods. J Phys Chem B. 1999; 103:8410-8426.
[cited by applicant]
Locker GY, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24:5313-5327. [PubMed: 17060676].
[cited by applicant]
Logozzi M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009; 4:e5219. [PubMed: 19381331].
[cited by applicant]
Logsdon CD, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003; 63:2649-2657. [PubMed: 12750293].
[cited by applicant]
Lowenfels AB, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993; 328:1433-1437. [PubMed: 8479461].
[cited by applicant]
Melo SA, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015; 523:177-182. [PubMed: 26106858].
[cited by applicant]
Miyazaki T, et al. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer. 2003; 103:657-663. [PubMed: 12494475].
[cited by applicant]
Mudali SV, et al. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis. 2006; 23:357-365. [PubMed: 17146615].
[cited by applicant]
Muralidharan-Chari V, et al. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010; 123:1603-1611. [PubMed: 20445011].
[cited by applicant]
Nusz GJ, et al. Label-free plasmonic detection of biomolecular binding by a single gold nanorod. Anal Chem. 2008; 80:984-989. [PubMed: 18197636].
[cited by applicant]
O'Driscoll L. Expanding on exosomes and ectosomes in cancer. N Engl J Med. 2015:372.
[cited by applicant]
Pei H, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009; 16:259-266. [PubMed: 19732725].
[cited by applicant]
Peinado H, et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med. 2012; 18:883-891. [PubMed: 22635005].
[cited by applicant]
Rabinowits G, et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009; 10:42-46. [PubMed: 19289371].
[cited by applicant]
Oldenburg et al., “Topics in Fluorescence Spectroscopy vol. 8 Radiative Decay Engineering”, Geddes, Springer, 333-346, 2005.
[cited by applicant]